Two injections, two entirely different jobs

The most common question patients bring to a first consultation is straightforward: which one should I have? The honest answer is that ChondroFiller® and Arthrosamid® are not really competing for the same job — they act on different parts of the knee, so the comparison is less like choosing between two brands of painkiller and more like deciding whether to repair the road surface or fix the drainage underneath it.

ChondroFiller® is an injectable collagen scaffold. Placed under ultrasound guidance as an outpatient injection, it coats the load-bearing cartilage surface at the ends of the bones. Once in situ, it works through acellular matrix-induced chondrogenesis — the scaffold recruits the patient's own progenitor cells to migrate in and support new cartilage matrix formation over the following months. It is, in the most literal sense, working on the structural surface that carries your body weight.

Arthrosamid® is something entirely different. It is a permanent polyacrylamide hydrogel (97.5% water, 2.5% cross-linked polyacrylamide) that integrates into the synovial membrane — the soft tissue lining the inside of the joint cavity. It does not regenerate cartilage. Its role is to cushion and modulate that lining, reducing the inflammation-driven pain signal that the synovium produces in osteoarthritis.

Because the two treatments target anatomically distinct structures within the same joint, the choice is not always either/or. For patients whose MRI shows both cartilage surface damage and an inflamed synovial lining, both can be delivered in a single outpatient appointment. Neither involves surgery or theatre admission.

What your MRI findings tell the consultant

Reading your MRI is where the clinical decision actually begins. A scan that shows cartilage surface loss — whether a focal chondral defect after injury or the diffuse wear of Kellgren-Lawrence Grade III or IV osteoarthritis — is the primary signal for ChondroFiller®. Because the injectable collagen scaffold has no defect-size limit, it suits both small localised lesions and more widespread joint degeneration affecting the load-bearing surfaces.

A different pattern of findings points toward Arthrosamid®: synovial thickening, an irritated joint lining, or inflammatory fluid accumulating within the joint cavity. These are the hallmarks of active synovitis — the situation where the soft tissue lining is generating a significant share of the pain signal, not just the worn cartilage surface.

Contraindications shift the decision considerably, and they matter for a practical reason: injecting either product into a mechanically unstable joint will not produce lasting benefit. If the assessment reveals untreated ligament instability, significant malalignment, or a meniscal deficit that is the underlying driver of cartilage wear, those structural issues generally need to be addressed before or alongside any injection therapy — otherwise the mechanical cause of further wear continues unchecked.

At MSK Doctors, the onMRI™ AI analysis layer can help quantify the distribution and severity of cartilage loss across the joint surfaces, adding objective measurement to the consultant's clinical reading of the scan and informing which treatment pathway is proportionate to the findings.

When ChondroFiller is the right fit

Active patients in their sixties and seventies who have been advised that knee replacement is the next logical step — but who want to explore whether the joint can be preserved — represent one of the clearest fits for ChondroFiller®. That profile extends in both directions: younger patients with a focal chondral defect following a sporting injury are equally appropriate candidates, as are those with more diffuse degenerative changes across the load-bearing surfaces at Kellgren-Lawrence Grade III or IV. The common clinical thread is cartilage surface damage confirmed on MRI.

The treatment works across two time horizons. From the moment the collagen gel is placed under ultrasound guidance, it acts as a physical cushion over worn articular surfaces — mechanical protection that begins immediately. Over the subsequent 6–12 months, a slower biological process unfolds: acellular matrix-induced chondrogenesis, in which the scaffold recruits the patient's own progenitor cells to migrate in and support new cartilage matrix formation. The scaffold creates the conditions; the body does the repair work.

For patients considering joint replacement, this two-phase action supports a genuine preservation argument — buying time and, in some cases, avoiding the need for surgery altogether rather than merely deferring it.

Published cohort data provide a realistic reference point for expectations: approximately a 30-point improvement on the IKDC (International Knee Documentation Committee) score, MOCART cartilage quality scores in the range of 70–87, and a documented complaint rate of approximately 0.06%. These are population-level findings from published series; individual outcomes depend on baseline cartilage condition and other joint factors. The entire pathway is delivered as an outpatient injection — no theatre admission, no general anaesthetic, no surgical wound.

When Arthrosamid makes more sense

For patients whose primary problem is an inflamed synovial lining rather than cartilage surface loss — or where both are present but surgery is not an acceptable or medically suitable route — Arthrosamid® offers a different kind of answer.

Arthrosamid® is not a regenerative treatment. The polyacrylamide hydrogel integrates permanently into the synovial membrane and cushions the joint lining, modulating the inflammatory pathway that generates much of the pain in moderate-to-severe osteoarthritis. Cartilage is not restored; the underlying joint degeneration continues. What the treatment provides is pain relief and improved function, sustained on average for 2–3 years from a single outpatient injection — a meaningful interval for patients who are not yet surgical candidates or who prefer to avoid replacement. Unlike hyaluronic acid, the material is not metabolised and does not require repeat courses in the same way.

The published evidence base is substantive. Bliddal et al. (J Orthop Surg Res, 2024) reported 12-month open-label follow-up data, building on an earlier 6-month prospective study from the same group (J Orthop Res Ther, 2021). An NHS study underway at the Robert Jones and Agnes Hunt Orthopaedic Hospital, funded by Contura Orthopaedics with a grant exceeding £150,000, is examining mechanism of action and patient selection in greater detail. Separately, Maulana, Cole, and Lee (J Arthritis, 2022) documented reductions in patellofemoral bone marrow lesions following a single injection — a finding that hints at structural benefit beyond symptom control, though it requires corroboration before firm conclusions can be drawn.

On the safety side, one aspect of the adverse-event profile warrants a direct conversation at consultation. Joint effusion — swelling within the knee — is the principal inflammatory adverse event to consider after Arthrosamid® injection. Published trial data have tended to capture this using patient-reported 'sensation of distension' rather than objective clinical or imaging confirmation, a methodological limitation that may underestimate how often clinically detectable effusion actually occurs. Published rates appear low, but patients should ask the treating consultant what frequency is observed in practice — that conversation, rather than the published figure alone, provides a more grounded basis for informed consent.

Combining both injections in a single appointment

The practical question, once each treatment's role is understood, becomes whether both can be given in the same appointment. In most cases where MRI confirms cartilage surface damage alongside synovial inflammation — each contributing independently to the patient's symptoms — the answer is yes, and combination delivery is offered within a single outpatient visit.

This is not a default protocol. The consultant reviews MRI findings to confirm that both pathologies are genuinely present and that the patient's overall profile supports two injections at the same session. When those conditions are met, each product is placed under ultrasound guidance into its respective anatomical location: ChondroFiller® onto the articular surface, Arthrosamid® into the synovial lining. Because the two targets do not overlap, there is no mechanistic conflict in combining them.

Each injection retains its distinct role throughout the treatment period — ChondroFiller® as the regenerative scaffold component supporting acellular matrix-induced chondrogenesis over the subsequent months; Arthrosamid® as the permanent hydrogel cushion modulating the synovial environment for pain relief. Describing them together as a generic 'combination filler' misrepresents what each product is doing and why.

For patients across Lincolnshire and the wider non-London region, the MSK Doctors Regeneration Hub in Sleaford and the MFO Life Sciences Lab in Grantham support specialist combination injection pathways — and both are accessible without a GP referral.

Evidence gaps and what to ask at your consultation

Neither treatment has been tested directly against the other in a randomised controlled trial — the choice between them rests on mechanism, MRI findings, and clinical expertise rather than head-to-head comparative data. That is not unusual for relatively recent injectable technologies, but naming it plainly helps patients approach the consultation with calibrated expectations.

Arthrosamid® currently has the larger peer-reviewed evidence base for knee osteoarthritis, with registry cohort data extending to 2–3 years and the NHS study at RJAH working to formalise patient-selection criteria. ChondroFiller® has a longer history as a collagen scaffold — it originated as an arthroscopic surgical implant before transitioning to injectable delivery — but post-injection cohort data are more recent, and long-term regeneration outcomes beyond two years in the injectable form are not yet as comprehensively documented as the surgical predecessor record. That gap is a realistic framing point, not a contraindication.

Three questions are worth raising at consultation:

• Does my MRI show cartilage surface damage, synovial inflammation, or evidence of both?
• Based on those findings, is combination delivery at a single appointment appropriate for my case?
• What outcomes are realistic at 12 and 24 months given my specific pattern of wear and joint grade?

The answers depend on individual anatomy and imaging — which is precisely why the consultation is where the decision gets made, not the comparison. You can book a consultation with the MSK Doctors team without a referral at mskdoctors.com.